Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1315-1320 |
| Number of pages | 6 |
| Journal | Cornea |
| Volume | 32 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2013 |
Fingerprint
ASJC Scopus subject areas
- Ophthalmology
Cite this
Vitreous and aqueous penetration of orally administered trimethoprim-sulfamethoxazole combination in humans. / Feiz, Vahid; Nijm, Lisa; Glickman, Randolph D.; Morse, Lawrence S.; Telander, David G.; Park, Susanna S.; Polage, Christopher R.; Christiansen, Steven M.; Moshirfar, Majid.
In: Cornea, Vol. 32, No. 10, 10.2013, p. 1315-1320.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vitreous and aqueous penetration of orally administered trimethoprim-sulfamethoxazole combination in humans
AU - Feiz, Vahid
AU - Nijm, Lisa
AU - Glickman, Randolph D.
AU - Morse, Lawrence S.
AU - Telander, David G.
AU - Park, Susanna S.
AU - Polage, Christopher R.
AU - Christiansen, Steven M.
AU - Moshirfar, Majid
PY - 2013/10
Y1 - 2013/10
N2 - Purpose: To determine the penetration of orally administered trimethoprim (TMP)-sulfamethoxazole (SMX) into the aqueous and vitreous cavity of noninflamed human eyes. Methods: Nine adult patients undergoing cataract surgery and 10 adult patients undergoing pars plana vitrectomy were given 3 doses of oral TMP-SMX every 12 hours before the surgery. Aqueous and blood samples were collected from patients undergoing cataract surgery; vitreous and blood samples were collected from patients undergoing vitrectomy. The levels of TMP and SMX were analyzed using high-performance liquid chromatography and were compared with the mean minimum inhibitory concentrations (MIC90) of potential ocular pathogens. Results: TMP-SMX was present in all samples. Among eyes undergoing cataract surgery, the mean concentrations of TMP in aqueous and blood were 0.341 ± 0.141 μg/mL (mean ± SD) and 1.501 ± 0.433 μg/mL and of SMX were 5.259 ± 0.929 μg/mL and 11.835 ± 2.100 μg/mL, respectively. Among eyes undergoing vitrectomy, the mean concentrations of TMP in vitreous and blood were 1.864 ± 0.807 μg/mL and 4.591 ± 2.979 μg/mL and of SMX were 5.910 ± 2.705 μg/mL and 39.289 ± 15.469 μg/mL, respectively. MIC90 levels were achieved against many bacterial pathogens, including methicillin-resistant Staphylococcus aureus. Conclusions: TMP-SMX penetrates both the aqueous and vitreous cavities when given orally. The components reach therapeutic inhibitory concentrations in the ocular cavity against many potential pathogens. Copyrigt
AB - Purpose: To determine the penetration of orally administered trimethoprim (TMP)-sulfamethoxazole (SMX) into the aqueous and vitreous cavity of noninflamed human eyes. Methods: Nine adult patients undergoing cataract surgery and 10 adult patients undergoing pars plana vitrectomy were given 3 doses of oral TMP-SMX every 12 hours before the surgery. Aqueous and blood samples were collected from patients undergoing cataract surgery; vitreous and blood samples were collected from patients undergoing vitrectomy. The levels of TMP and SMX were analyzed using high-performance liquid chromatography and were compared with the mean minimum inhibitory concentrations (MIC90) of potential ocular pathogens. Results: TMP-SMX was present in all samples. Among eyes undergoing cataract surgery, the mean concentrations of TMP in aqueous and blood were 0.341 ± 0.141 μg/mL (mean ± SD) and 1.501 ± 0.433 μg/mL and of SMX were 5.259 ± 0.929 μg/mL and 11.835 ± 2.100 μg/mL, respectively. Among eyes undergoing vitrectomy, the mean concentrations of TMP in vitreous and blood were 1.864 ± 0.807 μg/mL and 4.591 ± 2.979 μg/mL and of SMX were 5.910 ± 2.705 μg/mL and 39.289 ± 15.469 μg/mL, respectively. MIC90 levels were achieved against many bacterial pathogens, including methicillin-resistant Staphylococcus aureus. Conclusions: TMP-SMX penetrates both the aqueous and vitreous cavities when given orally. The components reach therapeutic inhibitory concentrations in the ocular cavity against many potential pathogens. Copyrigt
KW - Aqueous
KW - Bactrim
KW - Endophthalmitis
KW - Sulfamethoxazole
KW - Trimethoprim
KW - Vitrectomy
KW - Vitreous
UR - http://www.scopus.com/inward/record.url?scp=84886098908&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886098908&partnerID=8YFLogxK
U2 - 10.1097/ICO.0b013e318298ddf8
DO - 10.1097/ICO.0b013e318298ddf8
M3 - Article
C2 - 23928948
AN - SCOPUS:84886098908
VL - 32
SP - 1315
EP - 1320
JO - Cornea
JF - Cornea
SN - 0277-3740
IS - 10
ER -